Protagonist Therapeutics, Inc (PTGX) Stock Price, Financials & Summary

Price chart

Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22

Key dataOct 22, 2026

Open$138.00

From 52W high−12.04%

Volume403982.00

Market cap$9.03B

P/E (TTM)114.5x

P/S (TTM)32.0x

Div yield—

Key dataOct 22, 2026

Open

$138.00

From 52W high

−12.04%

Volume

403982.00

Market cap

$9.03B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

96.1x

P/E (TTM)

114.5x

RSI (14)

49.2

MomentumView details →

1D Return

+1.05%

YTD Return

+59.48%

SummaryUpdated Jun 1, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Newark, California. The company went public in August 2016 and specializes in discovering and developing peptide-based therapeutic drugs targeting hematology, blood disorders, and inflammatory diseases. Protagonist has evolved from a research-focused biotech startup into a company with multiple clinical-stage programs and strategic partnerships, including a significant collaboration with Janssen Biotech.

Ask drillr about Protagonist Therapeutics, Inc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

114.5x

EV/EBITDA

96.1x

EV/Sales

29.3x

P/S (TTM)

32.0x

P/B (TTM)

10.7x

ProfitabilityView details →

Gross Margin

99.86%

Net Margin

29.40%

EBITDA Margin

30.45%

ROE (TTM)

9.85%

ROA (TTM)

9.36%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

+34.81%

EPS YoY

+46.76%

FCF YoY

+256.27%

Revenue CAGR 3Y

+20.07%

EPS CAGR 3Y

—

EBITDA YoY

+110.49%

MomentumView details →

1D Return

+1.05%

YTD Return

+59.48%

1Y Return

+88.26%

RSI (14)

49.2

vs 50D SMA

−3.58%

vs 200D SMA

+21.32%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

21.71x

Quick Ratio

21.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$2.29

EPS Surprise

0.88%

Beats (12Q)

8/12

Next Q EPS Est

−$0.31

Avg Surprise (4Q)

825.87%

Rev Surprise

0.68%

Financials snapshotView financials →

Revenue (TTM)

281.99M

Net Income (TTM)

82.91M

Op. CF (TTM)

131.20M

Next earningsNov 5, 2026 →

Latest newsMore news →

Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.45d ago

Similar companies

Crinetics Pharmaceuticals, Inc.CRNX 中源协和600645.SH Caris Life Sciences, Inc.CAI Jiangsu Zenergy Battery Technologies Group Co., Ltd.03677.HK 热景生物688068.SH Kymera Therapeutics, Inc.KYMR Find similar companies →

Latest newsMore news →

Protagonist Therapeutics President and CEO Dinesh V. Patel sold 124,000 shares of the company's common stock for approximately $18.2 million between September 8 and September 10, 2026, under a pre-arranged 10b5-1 trading plan.43d ago Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.45d ago